Last reviewed · How we verify
JSKN003
JSKN003 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.
JSKN003 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced solid tumors (Phase 3 development).
At a glance
| Generic name | JSKN003 |
|---|---|
| Also known as | anti-Her2 ADC JSKN003 |
| Sponsor | Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
| Drug class | Bispecific antibody; immune checkpoint inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
JSKN003 functions as a bispecific antibody designed to target multiple immune regulatory pathways. By engaging dual immune checkpoints, it aims to overcome tumor immune evasion mechanisms and potentiate T cell-mediated anti-tumor immunity more effectively than single-target checkpoint inhibitors.
Approved indications
- Advanced solid tumors (Phase 3 development)
Common side effects
Key clinical trials
- JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan (PHASE3)
- Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors (PHASE1, PHASE2)
- A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer (PHASE2)
- JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects (PHASE3)
- JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors (PHASE1, PHASE2)
- First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors (PHASE1)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (PHASE2)
- JSKN003 Combined Treatment of HER2-positive Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JSKN003 CI brief — competitive landscape report
- JSKN003 updates RSS · CI watch RSS
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd portfolio CI